1. Randomized feasibility study of an autologous protein solution versus corticosteroids injection for treating subacromial pain in the primary care setting – the SPiRIT trial
- Author
-
Alex Woods, Anthony Howard, Nicholas Peckham, Ines Rombach, Asma Saleh, Juul Achten, Duncan Appelbe, Praveen Thamattore, and Stephen E. Gwilym
- Subjects
subacromial pain ,injection ,corticosteroid ,aps ,feasibility trial ,corticosteroids injection ,randomized controlled trial ,shoulder pain ,patient-reported outcome measures (proms) ,clinicians ,clinical outcomes ,subacromial impingement syndrome ,clinical diagnosis ,patient-reported outcome measurement information system ,blood ,Orthopedic surgery ,RD701-811 - Abstract
Aims: The primary aim of this study was to assess the feasibility of recruiting and retaining patients to a patient-blinded randomized controlled trial comparing corticosteroid injection (CSI) to autologous protein solution (APS) injection for the treatment of subacromial shoulder pain in a community care setting. The study focused on recruitment rates and retention of participants throughout, and collected data on the interventions’ safety and efficacy. Methods: Participants were recruited from two community musculoskeletal treatment centres in the UK. Patients were eligible if aged 18 years or older, and had a clinical diagnosis of subacromial impingement syndrome which the treating clinician thought was suitable for treatment with a subacromial injection. Consenting patients were randomly allocated 1:1 to a patient-blinded subacromial injection of CSI (standard care) or APS. The primary outcome measures of this study relate to rates of recruitment, retention, and compliance with intervention and follow-up to determine feasibility. Secondary outcome measures relate to the safety and efficacy of the interventions. Results: A total of 53 patients were deemed eligible, and 50 patients (94%) recruited between April 2022 and October 2022. Overall, 49 patients (98%) complied with treatment. Outcome data were collected in 100% of participants at three months and 94% at six months. There were no significant adverse events. Both groups demonstrated improvement in patient-reported outcome measures over the six-month period. Conclusion: Our study shows that it is feasible to recruit to a patient-blinded randomized controlled trial comparing APS and CSI for subacromial pain in terms of clinical outcomes and health-resource use in the UK. Safety and efficacy data are presented. Cite this article: Bone Jt Open 2024;5(7):534–542.
- Published
- 2024
- Full Text
- View/download PDF